AB Science S.A. (0Q77.L)
EUR 0.87
(-6.75%)
EUR 0.87
(-6.75%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 13.03 Million EUR | -21.89% |
| 2022 | 16.68 Million EUR | 4622.49% |
| 2021 | -369 Thousand EUR | 97.29% |
| 2020 | -13.6 Million EUR | -270.4% |
| 2019 | -3.67 Million EUR | 68.19% |
| 2018 | -11.54 Million EUR | 60.81% |
| 2017 | -29.45 Million EUR | -296.83% |
| 2016 | -7.42 Million EUR | -215.43% |
| 2015 | 6.43 Million EUR | -36.08% |
| 2014 | 10.05 Million EUR | 338.76% |
| 2013 | -4.21 Million EUR | 57.69% |
| 2012 | -9.95 Million EUR | 15.68% |
| 2011 | -11.8 Million EUR | -340.76% |
| 2010 | -2.67 Million EUR | -50.08% |
| 2009 | -1.78 Million EUR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -4.2 Million EUR | 0.0% |
| 2023 FY | 13.03 Million EUR | -21.89% |
| 2023 Q2 | 4.58 Million EUR | -5.06% |
| 2023 Q4 | 13.03 Million EUR | 2.34% |
| 2023 Q3 | 12.73 Million EUR | 177.98% |
| 2023 Q1 | 4.82 Million EUR | -71.08% |
| 2022 Q1 | 12.69 Million EUR | 3539.84% |
| 2022 Q3 | 20.11 Million EUR | 130.75% |
| 2022 Q4 | 16.68 Million EUR | -17.02% |
| 2022 FY | 16.68 Million EUR | 4622.49% |
| 2022 Q2 | 8.71 Million EUR | -31.34% |
| 2021 Q2 | -9.05 Million EUR | 0.79% |
| 2021 Q3 | 5.97 Million EUR | 166.02% |
| 2021 FY | -369 Thousand EUR | 97.29% |
| 2021 Q4 | -369 Thousand EUR | -106.18% |
| 2021 Q1 | -9.12 Million EUR | 32.93% |
| 2020 Q2 | -4.01 Million EUR | -140.89% |
| 2020 Q4 | -13.6 Million EUR | -1117.64% |
| 2020 Q1 | 9.82 Million EUR | 367.67% |
| 2020 Q3 | -1.11 Million EUR | 72.21% |
| 2020 FY | -13.6 Million EUR | -270.4% |
| 2019 Q2 | -1.16 Million EUR | -110.29% |
| 2019 Q4 | -3.67 Million EUR | -144.03% |
| 2019 Q3 | 8.34 Million EUR | 816.49% |
| 2019 Q1 | 11.31 Million EUR | 198.04% |
| 2019 FY | -3.67 Million EUR | 68.19% |
| 2018 Q2 | -11.77 Million EUR | 10.35% |
| 2018 FY | -11.54 Million EUR | 60.81% |
| 2018 Q4 | -11.54 Million EUR | -245.08% |
| 2018 Q3 | -3.34 Million EUR | 71.59% |
| 2018 Q1 | -13.13 Million EUR | 55.41% |
| 2017 Q3 | -27.73 Million EUR | 30.66% |
| 2017 Q4 | -29.45 Million EUR | -6.2% |
| 2017 Q1 | -37.19 Million EUR | -401.13% |
| 2017 Q2 | -39.99 Million EUR | -7.54% |
| 2017 FY | -29.45 Million EUR | -296.83% |
| 2016 Q1 | -5.77 Million EUR | -189.84% |
| 2016 FY | -7.42 Million EUR | -215.43% |
| 2016 Q4 | -7.42 Million EUR | -0.11% |
| 2016 Q3 | -7.41 Million EUR | -28.14% |
| 2016 Q2 | -5.78 Million EUR | -0.16% |
| 2015 Q4 | 6.43 Million EUR | -0.12% |
| 2015 FY | 6.43 Million EUR | -36.08% |
| 2015 Q3 | 6.43 Million EUR | -1.27% |
| 2015 Q1 | 6.52 Million EUR | -35.1% |
| 2015 Q2 | 6.52 Million EUR | -0.11% |
| 2014 Q4 | 10.05 Million EUR | -0.07% |
| 2014 Q2 | 4.14 Million EUR | 0.0% |
| 2014 Q1 | 4.14 Million EUR | 198.43% |
| 2014 FY | 10.05 Million EUR | 338.76% |
| 2014 Q3 | 10.06 Million EUR | 142.73% |
| 2013 Q1 | 5.38 Million EUR | 154.05% |
| 2013 Q2 | 5.38 Million EUR | 0.0% |
| 2013 Q3 | -4.21 Million EUR | -178.28% |
| 2013 Q4 | -4.21 Million EUR | 0.0% |
| 2013 FY | -4.21 Million EUR | 57.69% |
| 2012 Q4 | -9.95 Million EUR | 0.0% |
| 2012 Q2 | -19.33 Million EUR | 0.0% |
| 2012 FY | -9.95 Million EUR | 15.68% |
| 2011 FY | -11.8 Million EUR | -340.76% |
| 2011 Q4 | -11.8 Million EUR | 0.0% |
| 2011 Q2 | -5.32 Million EUR | 0.0% |
| 2010 Q2 | 1.36 Million EUR | 0.0% |
| 2010 FY | -2.67 Million EUR | -50.08% |
| 2010 Q4 | -2.67 Million EUR | 0.0% |
| 2009 FY | -1.78 Million EUR | 0.0% |
| 2009 Q4 | -1.78 Million EUR | 0.0% |
| 2009 Q2 | -4.76 Million EUR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Boiron SA | -60.34 Million EUR | 121.602% |
| Laboratorios Farmaceuticos Rovi, S.A. | 21.31 Million EUR | 38.84% |
| Vetoquinol SA | -129.83 Million EUR | 110.04% |
| Valneva SE | 82.73 Million EUR | 84.245% |
| Nanobiotix S.A. | -29.8 Million EUR | 143.742% |
| PHAXIAM Therapeutics S.A. | -275 Thousand EUR | 4840.0% |
| Vivoryon Therapeutics N.V. | -18.52 Million EUR | 170.368% |
| BioSenic S.A. | 28.04 Million EUR | 53.519% |
| ABIVAX Société Anonyme | -196.47 Million EUR | 106.634% |
| Formycon AG | 2.45 Million EUR | -431.824% |